We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

022100:KRXPOSCO DX COMPANY LTD. Analysis

Data as of 2026-06-06 - not real-time

₩29,200.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Posco Dx is trading at KRW 29,200, well above its DCF‑derived fair value of KRW 12,652, and its forward P/E of 52.6 markedly exceeds the industry average of 32.6, indicating a significant overvaluation. The stock sits below its 20‑day (KRW 33,160) and 50‑day (KRW 32,915) simple moving averages, while the MACD histogram is negative and the signal line is bearish, suggesting short‑term downward pressure. However, the broader trend is still classified as bullish, with a rising volume trend and a support level near KRW 28,800 that is close to the current price. The RSI at 41.5 is neutral, not yet in oversold territory, and the Fear‑Greed Index reads Extreme Greed, reflecting strong market sentiment despite the valuation gap.
Fundamentally, Posco Dx boasts a robust cash pile of KRW 266 bn against minimal debt, a modest dividend yield of 0.43 % with a payout ratio around 55 %, and a solid operating cash flow profile. Yet profitability metrics are thin—gross margin of 11 %, operating margin of 1.5 % and ROE of only 6.4 %—and revenue is contracting at a -18.6 % rate. The stock’s beta of 1.2 and 30‑day volatility of 90 % signal heightened market risk, while its technology‑focused sector adds a layer of sector‑specific uncertainty.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • price below 20‑day SMA
  • bearish MACD histogram
  • high forward P/E relative to peers

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • overall bullish trend direction
  • increasing volume and support near KRW 28,800
  • strong cash position offsetting thin margins

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • strategic exposure to smart factory and AI solutions
  • low debt and ample liquidity
  • valuation gap suggests price correction risk

Key Metrics & Analysis

Financial Health

Revenue Growth-18.60%
Profit Margin3.38%
P/E Ratio52.6
ROE6.37%
ROA3.14%
Debt/Equity0.38
Op. Cash Flow₩134.8B
Free Cash Flow₩125.5B
Industry P/E32.6

Technical Analysis

TrendBullish
RSI41.5
Support₩28,800.00
Resistance₩40,500.00
MA 20₩33,160.00
MA 50₩32,915.00
MA 200₩29,679.25
MACDBearish
VolumeIncreasing
Fear & Greed Index83.02

Valuation

Fair Value₩12,652.11
Target Price₩34,700.00
Upside/Downside18.84%
GradeOvervalued
TypeGrowth
Dividend Yield0.43%

Risk Assessment

Beta1.21
Volatility90.18%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.